US Patent

US11911446 — Use of C-type natriuretic peptide variants to treat skeletal dysplasia

Method of Use · Assigned to Biomarin Pharmaceutical Inc · Expires 2036-08-01 · 10y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the use of C-type natriuretic peptide variants to treat skeletal dysplasias and related disorders.

USPTO Abstract

The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.

Drugs covered by this patent

vosoritide (VOSORITIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3927`	—	vosoritide
`U-3927`	—	vosoritide
`U-3927`	—	vosoritide

Patent Metadata

Patent number: US11911446
Jurisdiction: US
Classification: Method of Use
Expires: 2036-08-01
Drug substance claim: No
Drug product claim: No
Assignee: Biomarin Pharmaceutical Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.